ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
CHICAGO, June 1, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response rate...
Daesang Makes First Appearance at Japan's Largest Food & Distribution Trade Show, SMTS 2026, Signaling Full-Scale Entry into the Japanese Market
- Held February 18–20 in Chiba, Japan, with approximately 2,200 exhibitors and over 70,000 expected visitors - Showcasing flagship products including Jongga Ilpum Kimchi and O'food Gochujang, alongside four tasting menus reflecting local food trends...
AWE Asia 2026 Concludes in Singapore, Signaling a More Grounded Phase for XR and AI
SINGAPORE, Feb. 7, 2026 /PRNewswire/ -- AWE Asia 2026 concluded this week at Singapore Expo, convening the global extended reality (XR) and artificial intelligence (AI) community for three days of keynotes, developer sessions, track discussions, and...